## **Betty Diamond**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3951792/publications.pdf

Version: 2024-02-01

156 13,242 48 110 papers citations h-index g-index

161 161 161 13943 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	HMGB1-mediated restriction of EPO signaling contributes to anemia of inflammation. Blood, 2022, 139, 3181-3193.	0.6	23
2	High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. Rheumatology, 2022, 61, 4335-4343.	0.9	6
3	Urine Proteomics and Renal <scp>Singleâ€Cell</scp> Transcriptomics Implicate Interleukinâ€16 in Lupus Nephritis. Arthritis and Rheumatology, 2022, 74, 829-839.	2.9	38
4	In utero exposure to maternal anti–aquaporin-4 antibodies alters brain vasculature and neural dynamics in male mouse offspring. Science Translational Medicine, 2022, 14, eabe9726.	5.8	11
5	Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. Open Forum Infectious Diseases, 2022, 9, .	0.4	5
6	IL-17–producing follicular Th cells enhance plasma cell differentiation in lupus-prone mice. JCI Insight, 2022, 7, .	2.3	3
7	Fc $\hat{I}^3$ RIIB regulates autoantibody responses by limiting marginal zone B cell activation. Journal of Clinical Investigation, 2022, 132, .	3.9	6
8	Anti-DNA antibodies., 2021,, 231-235.		0
9	Transcutaneous auricular vagus nerve stimulation reduces pain and fatigue in patients with systemic lupus erythematosus: a randomised, double-blind, sham-controlled pilot trial. Annals of the Rheumatic Diseases, 2021, 80, 203-208.	0.5	82
10	Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis and Rheumatology, 2021, 73, 121-131.	2.9	117
11	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. Annals of the Rheumatic Diseases, 2021, 80, 775-781.	0.5	37
12	Epinephrine Production in Th17 Cells and Experimental Autoimmune Encephalitis. Frontiers in Immunology, 2021, 12, 616583.	2.2	5
13	Cognitive Impairment in SLE: Mechanisms and Therapeutic Approaches. Current Rheumatology Reports, 2021, 23, 25.	2.1	4
14	Introducing the MAVEN Leadership Training Initiative to diversify the scientific workforce. ELife, 2021, 10, .	2.8	5
15	Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nature Communications, 2021, 12, 3391.	5.8	93
16	Follicular dendritic cell dysfunction contributes to impaired antigen-specific humoral responses in sepsis-surviving mice. Journal of Clinical Investigation, 2021, 131, .	3.9	8
17	Meant to B: B cells as a therapeutic target in systemic lupus erythematosus. Journal of Clinical Investigation, 2021, 131, .	3.9	27
18	HIF- $1\hat{l}\pm$ is a negative regulator of interferon regulatory factors: Implications for interferon production by hypoxic monocytes. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	31

#	Article	IF	CITATIONS
19	The magnitude of germinal center reactions is restricted by a fixed number of preexisting niches. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	13
20	Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. Lupus Science and Medicine, 2021, 8, e000522.	1.1	5
21	The brain in SLE. , 2021, , 231-255.		O
22	Contributions of Sex Chromosomes and Gonadal Hormones to the Male Bias in a Maternal Antibody-Induced Model of Autism Spectrum Disorder. Frontiers in Neurology, 2021, 12, 721108.	1.1	1
23	Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosus. Lupus Science and Medicine, 2021, 8, e000559.	1.1	10
24	The intersection of COVID-19 and autoimmunity. Journal of Clinical Investigation, 2021, 131, .	3.9	138
25	1509â€Differences in chromatin architecture pre- and post-induction therapy in pediatric lupus patients. , 2021, , .		0
26	A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis. Rheumatology, 2020, 59, 1505-1513.	0.9	3
27	Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. Arthritis Care and Research, 2020, 72, 233-242.	1.5	17
28	Design and application of single-cell RNA sequencing to study kidney immune cells in lupus nephritis. Nature Reviews Nephrology, 2020, 16, 238-250.	4.1	48
29	SARS-CoV-2 and interferon blockade. Molecular Medicine, 2020, 26, 103.	1.9	3
30	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Annals of the Rheumatic Diseases, 2020, 79, 1333-1339.	0.5	35
31	The renin–angiotensin system: An integrated view of lung disease and coagulopathy in COVID-19 and therapeutic implications. Journal of Experimental Medicine, 2020, 217, .	4.2	21
32	In utero exposure to endogenous maternal polyclonal anti-Caspr2 antibody leads to behavioral abnormalities resembling autism spectrum disorder in male mice. Scientific Reports, 2020, 10, 14446.	1.6	12
33	HMGB1 in Systemic Lupus Erythematosus. Frontiers in Immunology, 2020, 11, 1057.	2.2	35
34	Lupus autoantibodies act as positive allosteric modulators at GluN2A-containing NMDA receptors and impair spatial memory. Nature Communications, 2020, 11, 1403.	5.8	36
35	Using the Mouse to Model Human Diseases: Cognitive Impairment in Systemic Lupus Erythematosus. Journal of Rheumatology, 2020, 47, 1145-1149.	1.0	3
36	Integrated urine proteomics and renal single-cell genomics identify an IFN- $\hat{l}^3$ response gradient in lupus nephritis. JCI Insight, 2020, 5, .	2.3	57

3

#	Article	IF	CITATIONS
37	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 1151-1159.	0.5	759
38	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1400-1412.	2.9	1,098
39	HMGB1–C1q complexes regulate macrophage function by switching between leukotriene and specialized proresolving mediator biosynthesis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23254-23263.	3.3	64
40	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 634-640.	0.5	51
41	Maternal Antibody and ASD: Clinical Data and Animal Models. Frontiers in Immunology, 2019, 10, 1129.	2.2	14
42	The immune cell landscape in kidneys of patients with lupus nephritis. Nature Immunology, 2019, 20, 902-914.	7.0	501
43	Metabolic and microstructural alterations in the SLE brain correlate with cognitive impairment. JCI Insight, 2019, 4, .	2.3	52
44	Cognitive Dysfunction in Systemic Lupus Erythematosus: A Case for Initiating Trials. Arthritis and Rheumatology, 2019, 71, 1413-1425.	2.9	41
45	Investigational treatment of rheumatoid arthritis with a vibrotactile device applied to the external ear. Bioelectronic Medicine, 2019, 5, 4.	1.0	55
46	Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ Open, 2019, 9, e025687.	0.8	81
47	Alterations in Blood-Brain Barrier Permeability in Patients with Systemic Lupus Erythematosus. American Journal of Neuroradiology, 2019, 40, 470-477.	1.2	28
48	Dynamic Contrast-Enhanced MRI Reveals Unique Blood-Brain Barrier Permeability Characteristics in the Hippocampus in the Normal Brain. American Journal of Neuroradiology, 2019, 40, 408-411.	1.2	18
49	Reply:. American Journal of Neuroradiology, 2019, 40, E42-E43.	1.2	1
50	178â€Phase 2 trial of induction therapy with anti-CD20 (Rituximab) followed by maintenance therapy with anti-BAFF (Belimumab) in patients with active lupus nephritis. , 2019, , .		0
51	204â€The immune cell landscape in kidneys of lupus nephritis patients. , 2019, , .		2
52	ABO167â€SINGLE CELL RNA EXPRESSION IN LUPUS NEPHRITIS COMPARING AFRICAN-AMERICAN AND CAUCA PATIENTS IDENTIFIES DIFFERENTIAL EXPRESSION OF TYPE I INTERFERON PATHWAY., 2019,,.	SIAN	0
53	Effect of vitamin D on serum markers of bone turnover in SLE in a randomised controlled trial. Lupus Science and Medicine, 2019, 6, e000352.	1.1	3
54	205â€Single cell RNA expression in lupus nephritis comparing african-american and caucasian patients identifies differential expression of type I interferon pathway. , 2019, , .		0

#	Article	IF	Citations
55	<i>Reply:</i> . American Journal of Neuroradiology, 2019, 40, E67-E68.	1.2	0
56	Assessing cognitive impairment in SLE: examining relationships between resting glucose metabolism and anti-NMDAR antibodies with navigational performance. Lupus Science and Medicine, 2019, 6, e000327.	1.1	11
57	Buprenorphine Markedly Elevates a Panel of Surrogate Markers in a Murine Model of Sepsis. Shock, 2019, 52, 550-553.	1.0	14
58	Loss of an IgG plasma cell checkpoint in patients with lupus. Journal of Allergy and Clinical Immunology, 2019, 143, 1586-1597.	1.5	36
59	Patterns of ANA+ B cells for SLE patient stratification. JCI Insight, 2019, 4, .	2.3	25
60	PD-1hiCXCR5– T peripheral helper cells promote B cell responses in lupus via MAF and IL-21. JCI Insight, 2019, 4, .	2.3	171
61	Reduced expression of inflammation regulatory proteins, ETSâ€l and TNIPâ€l, may cause lupus in humans. FASEB Journal, 2019, 33, 523.4.	0.2	0
62	Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder. Arthritis and Rheumatology, 2018, 70, 277-286.	2.9	45
63	TD-05â€Dynamic contrast enhanced MRI (DCE-MRI) demonstrates hippocampus permeability in SLE. , 2018, , .		0
64	CT-03â€Phase 2 trial of induction therapy with anti-CD20 (rituximab) followed by maintenance therapy with anti-BAFF (belimumab) in patients with active lupus nephritis. , 2018, , .		0
65	Al-19â€T peripheral helper cells are expanded in the circulation of active SLE patients and correlate with CD21 <sup>low</sup> B cells., 2018,,.		2
66	DNA-Mediated Interferon Signature Induction by SLE Serum Occurs in Monocytes Through Two Pathways: A Mechanism to Inhibit Both Pathways. Frontiers in Immunology, 2018, 9, 2824.	2.2	32
67	Constitutive Vagus Nerve Activation Modulates Immune Suppression in Sepsis Survivors. Frontiers in Immunology, 2018, 9, 2032.	2.2	22
68	Lupus antibodies induce behavioral changes mediated by microglia and blocked by ACE inhibitors. Journal of Experimental Medicine, 2018, 215, 2554-2566.	4.2	117
69	Mutations of Recombinant Aquaporin-4 Antibody in the Fc Domain Can Impair Complement-Dependent Cellular Cytotoxicity and Transplacental Transport. Frontiers in Immunology, 2018, 9, 1599.	2.2	4
70	Follicular Helper T Cells in Systemic Lupus Erythematosus. Frontiers in Immunology, 2018, 9, 1793.	2,2	68
71	Plasma Cell Differentiation Pathways in Systemic Lupus Erythematosus. Frontiers in Immunology, 2018, 9, 427.	2.2	102
72	Immunization Elicits Antigen-Specific Antibody Sequestration in Dorsal Root Ganglia Sensory Neurons. Frontiers in Immunology, 2018, 9, 638.	2.2	15

#	Article	IF	Citations
73	High-Mobility Group Box 1-Induced Complement Activation Causes Sterile Inflammation. Frontiers in Immunology, 2018, 9, 705.	2.2	51
74	Lineage-Specific Functionality of an Interferon Regulatory Factor 5 Lupus Risk Haplotype: Lack of B Cell Intrinsic Effects. Frontiers in Immunology, 2018, 9, 996.	2.2	16
75	Targeting DEC-205â^'DCIR2+ dendritic cells promotes immunological tolerance in proteolipid protein-induced experimental autoimmune encephalomyelitis. Molecular Medicine, 2018, 24, 17.	1.9	32
76	Serologic features of cohorts with variable genetic risk for systemic lupus erythematosus. Molecular Medicine, 2018, 24, 24.	1.9	12
77	B-Cell Mediated Humoral Responses Are Impaired in Sepsis Survivors. Blood, 2018, 132, 1123-1123.	0.6	0
78	Evidence for C1q-mediated crosslinking of CD33/LAIR-1 inhibitory immunoreceptors and biological control of CD33/LAIR-1 expression. Scientific Reports, 2017, 7, 270.	1.6	43
79	A structural investigation of FISLE-412, a peptidomimetic compound derived from saquinavir that targets lupus autoantibodies. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4725-4729.	1.0	6
80	Increased cathepsin S in Prdm1â^'/â^' dendritic cells alters the TFH cell repertoire and contributes to lupus. Nature Immunology, 2017, 18, 1016-1024.	7.0	86
81	Correlation of hypogammaglobulinaemia with proteinuria, and the relationship between hypogammaglobulinaemia and infection in active lupus nephritis. Lupus Science and Medicine, 2017, 4, e000229.	1.1	8
82	The Role of Brain-Reactive Autoantibodies in Brain Pathology and Cognitive Impairment. Frontiers in Immunology, 2017, 8, 1101.	2.2	42
83	Checkpoints for Autoreactive B Cells in the Peripheral Blood of Lupus Patients Assessed by Flow Cytometry. Arthritis and Rheumatology, 2016, 68, 2210-2220.	2.9	65
84	Molecular signatures in systemic lupus erythematosus: distinction between disease flare and infection. Lupus Science and Medicine, 2016, 3, e000159.	1.1	37
85	C1q and HMGB1 reciprocally regulate human macrophage polarization. Blood, 2016, 128, 2218-2228.	0.6	130
86	Blood pressure regulation by CD4+ lymphocytes expressing choline acetyltransferase. Nature Biotechnology, 2016, 34, 1066-1071.	9.4	74
87	<scp>SLE</scp> â€associated risk factors affect <scp>DC</scp> function. Immunological Reviews, 2016, 269, 100-117.	2.8	18
88	DNA-reactive B cells in lupus. Current Opinion in Immunology, 2016, 43, 1-7.	2.4	25
89	Blood-Brain Barrier Deterioration and Hippocampal Gene Expression in Polymicrobial Sepsis: An Evaluation of Endothelial MyD88 and the Vagus Nerve. PLoS ONE, 2016, 11, e0144215.	1.1	13
90	Inhibition of Human Erythropoiesis during Inflammation Is Mediated By High Mobility Group Box Protein 1 (HMGB1) through Decreased Commitment of Hematopoietic Stem Cells to the Erythroid Lineage and By Increased Apoptosis of Terminally Differentiating Erythroblasts. Blood, 2016, 128, 702-702.	0.6	0

#	Article	IF	CITATIONS
91	Immune-mediated brain pathology: from autoantibodies to microglia. Discovery Medicine, 2016, 22, 201-207.	0.5	3
92	Introduction to immunology at Feinstein Institute for Medical Research (FIMR). Immunologic Research, 2015, 63, 1-2.	1.3	1
93	Maternal antibodies and developing blood–brain barrier. Immunologic Research, 2015, 63, 18-25.	1.3	26
94	Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial of the Effect of Vitamin D <sub>3</sub> on the Interferon Signature in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2015, 67, 1848-1857.	2.9	73
95	Autoimmune Disease–Associated Haplotypes of <i>BLK</i> Exhibit Lowered Thresholds for B Cell Activation and Expansion of Ig Classâ€5witched B Cells. Arthritis and Rheumatology, 2015, 67, 2866-2876.	2.9	35
96	HMGB1 Mediates Anemia of Inflammation in Murine Sepsis Survivors. Molecular Medicine, 2015, 21, 951-958.	1.9	45
97	The Genotype and Phenotype (GaP) registry: a living biobank for the analysis of quantitative traits. Immunologic Research, 2015, 63, 107-112.	1.3	14
98	Therapeutics to block autoantibody initiation and propagation in systemic lupus erythematosus and rheumatoid arthritis. Science Translational Medicine, 2015, 7, 280ps5.	5 <b>.</b> 8	17
99	Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. Journal of Clinical Investigation, 2015, 125, 2194-2202.	3.9	232
100	Commentary: Crossing the Atlantic: The Euro‣upus Nephritis Regimen in North America. Arthritis and Rheumatology, 2015, 67, 1144-1146.	2.9	22
101	Brain metabolism and autoantibody titres predict functional impairment in systemic lupus erythematosus. Lupus Science and Medicine, 2015, 2, e000074-e000074.	1.1	34
102	Antibodies as Mediators of Brain Pathology. Trends in Immunology, 2015, 36, 709-724.	2.9	47
103	Fundamental role of C1q in autoimmunity and inflammation. Immunologic Research, 2015, 63, 101-106.	1.3	55
104	Selective Impairment of Spatial Cognition Caused by Autoantibodies to the N-Methyl-d-Aspartate Receptor. EBioMedicine, 2015, 2, 755-764.	2.7	71
105	DNA-Containing Immunocomplexes Promote Inflammasome Assembly and Release of Pyrogenic Cytokines by CD14 <sup>+</sup> CD16 <sup>+</sup> CD64 <sup>high</sup> CD32 <sup>low</sup> Inflammatory Monocytes from Malaria Patients. MBio, 2015, 6, e01605-15.	1.8	37
106	Modulation of tolerogenic dendritic cells and autoimmunity. Seminars in Cell and Developmental Biology, 2015, 41, 49-58.	2.3	40
107	Letter from Incoming Editor in Chief of Molecular Medicine, Dr. Betty Diamond. Molecular Medicine, 2014, 20, 331-331.	1.9	0
108	C1q-Mediated Repression of Human Monocytes Is Regulated by Leukocyte-Associated Ig-Like Receptor 1 (LAIR-1). Molecular Medicine, 2014, 20, 559-568.	1.9	56

#	Article	IF	Citations
109	Expression of Blimp-1 in Dendritic Cells Modulates the Innate Inflammatory Response in Dextran Sodium Sulfate-Induced Colitis. Molecular Medicine, 2014, 20, 707-719.	1.9	22
110	The gut microbiota influences blood-brain barrier permeability in mice. Science Translational Medicine, 2014, 6, 263ra158.	5.8	1,589
111	Regional Brain Metabolism in a Murine Systemic Lupus Erythematosus Model. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 1315-1320.	2.4	23
112	Comparative transcriptional and functional profiling defines conserved programs of intestinal DC differentiation in humans and mice. Nature Immunology, 2014, 15, 98-108.	7.0	231
113	Hormonal milieu at time of B cell activation controls duration of autoantibody response. Journal of Autoimmunity, 2014, 53, 46-54.	3.0	26
114	Regulation of dendritic cell activation by microRNA let-7c and BLIMP1. Journal of Clinical Investigation, 2013, 123, 823-33.	3.9	68
115	C1q limits dendritic cell differentiation and activation by engaging LAIR-1. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3160-7.	3.3	149
116	HMGB1 Mediates Cognitive Impairment in Sepsis Survivors. Molecular Medicine, 2012, 18, 930-937.	1.9	172
117	Female mouse fetal loss mediated by maternal autoantibody. Journal of Experimental Medicine, 2012, 209, 1083-1089.	4.2	42
118	A model for lupus brain disease. Immunological Reviews, 2012, 248, 56-67.	2.8	49
119	Mapping the immunological homunculus. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3461-3462.	3.3	27
120	Structural modification of DNA—a therapeutic option in SLE?. Nature Reviews Rheumatology, 2011, 7, 733-738.	3.5	28
121	Differences in Regional Brain Activation Patterns Assessed by Functional Magnetic Resonance Imaging in Patients with Systemic Lupus Erythematosus Stratified by Disease Duration. Molecular Medicine, 2011, 17, 1349-1356.	1.9	39
122	It takes guts to grow a brain. BioEssays, 2011, 33, 588-591.	1.2	56
123	Tolerogenic function of Blimp-1 in dendritic cells. Journal of Experimental Medicine, 2011, 208, 2193-2199.	4.2	122
124	Effect of longâ€term belimumab treatment on b cells in systemic lupus erythematosus: Extension of a phase II, doubleâ€blind, placeboâ€controlled, doseâ€ranging study. Arthritis and Rheumatism, 2010, 62, 201-210.	6.7	198
125	Enhanced Selection of High Affinity DNA-Reactive B Cells Following Cyclophosphamide Treatment in Mice. PLoS ONE, 2010, 5, e8418.	1.1	26
126	Antibodies and the Brain: Lessons from Lupus. Journal of Immunology, 2010, 185, 2637-2640.	0.4	29

#	Article	IF	CITATIONS
127	Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18569-18574.	3.3	184
128	Neurotoxic autoantibodies mediate congenital cortical impairment of offspring in maternal lupus. Nature Medicine, 2009, 15, 91-96.	15.2	150
129	Losing your nerves? Maybe it's the antibodies. Nature Reviews Immunology, 2009, 9, 449-456.	10.6	220
130	Polyreactive autoantibodies in systemic lupus erythematosus have pathogenic potential. Journal of Autoimmunity, 2009, 33, 270-274.	3.0	82
131	Identification of DNA-reactive B cells in patients with systemic lupus erythematosus. Journal of Immunological Methods, 2008, 338, 79-84.	0.6	19
132	Increased IL-12 inhibits B cells' differentiation to germinal center cells and promotes differentiation to short-lived plasmablasts. Journal of Experimental Medicine, 2008, 205, 2437-2448.	4.2	33
133	Serum and Cerebrospinal Fluid Autoantibodies in Patients with Neuropsychiatric Lupus Erythematosus. Implications for Diagnosis and Pathogenesis. PLoS ONE, 2008, 3, e3347.	1.1	156
134	Contribution of BAFF and DNAâ€containing Immune Complexes to the Generation of DNAâ€reactive B cells. FASEB Journal, 2008, 22, 668.17.	0.2	0
135	Use of computerized assessment to predict neuropsychological functioning and emotional distress in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2006, 55, 434-441.	6.7	66
136	Immunity and behavior: Antibodies alter emotion. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 678-683.	3.3	264
137	Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19854-19859.	3.3	365
138	Similarities and differences between selective and nonselective BAFF blockade in murine SLE. Journal of Clinical Investigation, 2006, 116, 724-734.	3.9	196
139	Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus. New England Journal of Medicine, 2005, 353, 2550-2558.	13.9	962
140	Mechanism of Action of Transmembrane Activator and Calcium Modulator Ligand Interactor-Ig in Murine Systemic Lupus Erythematosus. Journal of Immunology, 2004, 173, 3524-3534.	0.4	128
141	Cognition and Immunity. Immunity, 2004, 21, 179-188.	6.6	386
142	The immune tolerance network and rheumatic disease: Immune tolerance comes to the clinic. Arthritis and Rheumatism, 2001, 44, 1730-1735.	6.7	16
143	A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nature Medicine, 2001, 7, 1189-1193.	15.2	721
144	T Cell Studies in a Peptide-Induced Model of Systemic Lupus Erythematosus. Journal of Immunology, 2001, 166, 1667-1674.	0.4	40

#	Article	IF	CITATIONS
145	Molecular mimicry between bacterial and self antigen in a patient with systemic lupus erythematosus. European Journal of Immunology, 1999, 29, 1901-1911.	1.6	65
146	Bcl-2 leads to expression of anti-DNA B cells but no nephritis: a model for a clinical subset. European Journal of Immunology, 1999, 29, 3168-3178.	1.6	38
147	Immunization with a Peptide Surrogate for Double-stranded DNA (dsDNA) Induces Autoantibody Production and Renal Immunoglobulin Deposition. Journal of Experimental Medicine, 1998, 188, 29-38.	4.2	184
148	Light Chain Usage in Anti–double-stranded DNA B Cell Subsets: Role in Cell Fate Determination. Journal of Experimental Medicine, 1997, 185, 1317-1326.	4.2	66
149	lgG+, CD5+Human Chronic Lymphocytic Leukemia B Cells. Production of lgG Antibodies That Exhibit Diminished Autoreactivity and lgG Subclass Skewing. Autoimmunity, 1994, 19, 39-48.	1.2	15
150	The Preferential Expression of the Anti-DNA Associated 8.12 Idiotype in Lupus is not Genetically Controlled. Autoimmunity, 1994, 18, 1-6.	1.2	11
151	Characterization of two Human Anti-DNA Antibodies Bearing the Pathogenic Idiotype 8.12. Autoimmunity, 1993, 16, 13-21.	1.2	14
152	Lupus anti-DNA antibodies bearing the 8.12 idiotype appear to be somatically mutated. Journal of Clinical Immunology, 1992, 12, 11-16.	2.0	4
153	Genetic recombination in the $\hat{l}\pm 2$ domain of the $\hat{El}\pm$ chain yields an Ed molecule with altered T cell activation. European Journal of Immunology, 1990, 20, 2571-2576.	1.6	3
154	Pathogenic Anti-DNA Antibodies in SLE: Idiotypic Families and Genetic Origins. International Reviews of Immunology, 1990, 5, 295-313.	1.5	36
155	The generation of human monocyte/macrophage cell lines. Nature, 1983, 306, 597-599.	13.7	63
156	Mimicry between DNA, Carbohydrates, and Peptides: Implications in Systemic Lupus Erythematosus. , 0, , 127-141.		1